Abstract
The purpose was to characterize the hemostatic changes in women with gestational diabetes mellitus (GDM). In this case–control study, 50 women with newly diagnosed GDM at 24–28 weeks of pregnancy and 41 normal pregnant women, matched for age, body mass index, and gestational age, were enrolled. Anthropometric, metabolic patterns, coagulation parameters, and plasminogen were measured in each subject. Plasma fibrinogen levels, plasminogen, and von Willebrand factor (vWF) activities were significantly higher in patients with GDM as compared to normal pregnant women (p < 0.001, p < 0.001, and p < 0.05, respectively). Although protein S was significantly elevated in diabetic group (p < 0.05), free protein S was similar in both groups. Coagulation factors VIII and IXa were significantly higher in patients with GDM (p < 0.001 and p < 0.01, respectively). In the group with GDM, factor VIII was positively correlated with HbA1c (r = 0.192, p < 0.001). A weak but significant negative correlation was observed between protein S and fasting glucose (r =−0.006, p < 0.05). GDM potentiates the alteration in coagulation and fibrinolysis during normal pregnancy. The question of whether the hemostatic balance is unchanged or shifts toward a hypercoagulable status remains unanswered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thornton P, Douglas J. Coagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2010;24:339–52. doi:10.1016/j.bpobgyn.2009.11.010.
Lee CA, Chi C, Pavord SR, UK Haemophilia Centre Doctors’ Organization, et al. The obstetric and gynaecological management of women with inherited bleeding disorders—review with guidelines produced by a task force of UK Haemophilia Centre Doctors’ Organization. Haemophilia. 2006;12(4):301–36. doi:10.1111/j.1365- 2516.2006.01314.x.
Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol. 1995;172(1 Pt 1):147–50.
Abdel Gader AG, Khashoggi TY, Habib F, Awadallah SB. Haemostatic and cytokine changes in gestational diabetes mellitus. Gynecol Endocrinol. 2011;27(5):356–60. doi:10.3109/09513590.2010.495241.
Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles RM, Cabero L. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes. Am J Perinatol. 1998;15(8):479–86. doi:10.1055/s-2007-994069.
Liu BY, Jian YL, Zhong M, Yu YH, Wang Q, Zhang J. Value of coagulation function and fibrinolytic system assessment in patients with gestational diabetes mellitus (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao. 2007;27(1):35–7.
American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30:S4–S41. doi:10.2337/dc07-S004.
Kruszynska Y, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes mellitus and in lean and obese normal subjects. Diabetes. 2000;49(4):633–9. doi:10.2337/diabetes.49.4.633.
Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003;92(11):1362–5. doi:10.1016/j.amjcard.2003.08.033.
Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss 3rd JF, Petraglia F. Inflammation and pregnancy. Reprod Sci. 2009;16(2):206–15. doi:10.1177/1933719108329095.
Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated haemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med. 2002;126(11):1405–14.
Bertina RM, van Wijngaarden A, Reinald-Poot J, Poort SR, Bom VJ. Determination of plasma protein S—the protein cofactor of activated protein C. Thromb Haemost. 1985;53(2):268–72.
O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003;17(3):385–96. doi:10.1016/S1521-6934(03)00019-1.
Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study. Br J Haematol. 1999;105(1):110–6. doi:10.1111/j.1365-2141.1999.01317.x.
Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med. 2002;113(8):636–42. doi:10.1016/S0002-9343(02)01345-1.
Lowe GD. Factor IX and thrombosis. Br J Haematol. 2001;115(3):507–13. doi:10.1046/j.1365-2141.2001.03186.x.
Cadroy Y, Grandjean H, Pichon J, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or preeclampsia. Br J Obstet Gynaecol. 1993;100(5):416–20.
Akinci B, Demir T, Saygili S, et al. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy. Diabetes Res Clin Pract. 2008;81(1):93–6. doi:10.1016/j.diabres.2008.03.003.
Won HS, Kim DY, Yang MS, Lee SJ, Shin HH, Park JB. Pregnancy-induced hypertension, but not gestational diabetes mellitus, is a risk factor for venous thromboembolism in pregnancy. Korean Circ J. 2011;41(1):23–7. doi:10.4070/kcj.2011.41.1.23.
Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium—a register-based case–control study. Am J Obstet Gynecol. 2008;198(2):233.e1–7. doi:10.1016/j.ajog.2007.08.041.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bekdemir, H., Berberoglu, Z., Gorar, S. et al. Hemostatic changes in gestational diabetes mellitus. Int J Diabetes Dev Ctries 35 (Suppl 3), 502–506 (2015). https://doi.org/10.1007/s13410-015-0288-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13410-015-0288-1